RiboMed receives second patent on abscription-based molecular detection:

RM_logo  RiboMed Biotechnologies, Inc. announced that the United States Patent Office has issued its second patent for their novel isothermal molecular detection process, Abscription™. The patent, entitled “Molecular Detection Systems Utilizing Reiterative Oligonucleotide Synthesis” covers additional elements in methods for detecting the presence of target molecules by generating multiple copies of short target-specific oligonucleotides. This signal generation method, the basis of RiboMed’s RiboMaker Detection System, is a robust, PCR-free process for detecting proteins and nucleic acids without target amplification. The first patent focused primarily on detecting a DNA modification, methylation of CpG sites that occur very early in cancer and other diseases.

Advertisements

Comments are closed.